Therapeutically triggering an innate immune response in a target tissue

A method for improving efficacy of a site specific immunotherapy (SSI) treatment of a human patient having Crohn's disease, wherein the SSI treatment comprises treatment with a formulation comprising a whole, killed or attenuated E. coli that is pathogenic in the gastrointestinal tract, the method comprising:

• measuring or having measured in vitro a level of two or more of IFNgamma, IL-12P70 and IL-17A protein in a serum sample from the patient undergoing the SSI treatment;
• and
• treating the patient with an adjusted dosage and/or dosage regimen of the SSI treatment based on the measured level of IFNgamma, IL-12P70 and/or IL-17A to thereby increase the level of IFNgamma, IL-12P70 and/or IL-17A in a subsequent serum sample from the patient undergoing the SSI treatment with the adjusted dosage and/or dosage regimen.